Cara Therapeutics
Stock Forecast, Prediction & Price Target
Cara Therapeutics Financial Estimates
Cara Therapeutics Revenue Estimates
Cara Therapeutics EBITDA Estimates
Cara Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $23.02M N/A | $41.86M 81.80% | $20.96M -49.91% | Avg: $7.39M Low: $3.59M High: $14.45M avg. -64.73% | Avg: $8.02M Low: $4.84M High: $13.75M avg. 8.57% | Avg: $17.32M Low: $10.45M High: $29.67M avg. 115.75% | Avg: $58.73M Low: $35.44M High: $100.64M avg. 239.08% |
Net Income
% change YoY
| $-88.19M N/A | $-83.41M 5.41% | $-118.51M -42.07% | Avg: $-44.32M Low: $-55.77M High: $-18.41M avg. 62.60% | Avg: $-39.86M Low: $-33.57M High: $-17.32M avg. 10.04% | Avg: $-46.35M Low: $-89.34M High: $-22.45M avg. -16.25% | Avg: $-34.43M Low: $-66.38M High: $-16.68M avg. 25.70% |
EBITDA
% change YoY
| $-89.08M N/A | $-87.53M 1.73% | $-117.65M -34.40% | Avg: $-5.85M Low: $-11.44M High: $-2.84M avg. 95.02% | Avg: $-6.35M Low: $-10.89M High: $-3.83M avg. -8.57% | Avg: $-13.71M Low: $-23.49M High: $-8.27M avg. -115.75% | Avg: $-46.49M Low: $-79.67M High: $-28.05M avg. -239.08% |
EPS
% change YoY
| -$1.74 N/A | -$1.55 10.91% | -$2.19 -41.29% | Avg: -$0.74 Low: -$1.03 High: -$0.34 avg. 66.43% | Avg: -$0.47 Low: -$0.62 High: -$0.32 avg. 36.50% | Avg: -$0.86 Low: -$1.65 High: -$0.41 avg. -83.42% | Avg: -$0.64 Low: -$1.23 High: -$0.31 avg. 25.70% |
Operating Expenses
% change YoY
| $112.11M N/A | $122.13M 8.94% | $136.28M 11.58% | Avg: $6.46M Low: $3.14M High: $12.63M avg. -95.25% | Avg: $7.01M Low: $4.23M High: $12.02M avg. 8.57% | Avg: $15.14M Low: $9.13M High: $25.95M avg. 115.75% | Avg: $51.35M Low: $30.98M High: $87.99M avg. 239.08% |
FAQ
What is Cara Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.52% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -55.77M, average is -44.32M and high is -18.41M.
What is Cara Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 74.66% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $3.59M, average is $7.39M and high is $14.45M.
What is Cara Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 11.30% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.03, average is -$0.74 and high is $-0.34.
What is the best performing analyst?
In the last twelve months analysts have been covering Cara Therapeutics stock. The most successful analyst is Sumant Kulkarni.